Cargando…

A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control

The combination of immune-stimulating strategies has the potency to improve immunotherapy of cancer. Vaccination against neoepitopes derived from patient tumor material can generate tumor-specific T cell immunity, which could reinforce the efficacy of checkpoint inhibitor therapies such as anti-PD-1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tondini, Elena, Arakelian, Tsolere, Oosterhuis, Koen, Camps, Marcel, van Duikeren, Suzanne, Han, Wanda, Arens, Ramon, Zondag, Gerben, van Bergen, Jeroen, Ossendorp, Ferry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791440/ https://www.ncbi.nlm.nih.gov/pubmed/31646082 http://dx.doi.org/10.1080/2162402X.2019.1652539

Ejemplares similares

Dominant Antiviral CD8(+) T Cell Responses Empower Prophylactic Antibody-Eliciting Vaccines Against Cytomegalovirus
por: Pardieck, Iris N., et al.
Publicado: (2022)

PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors
por: Beyrend, Guillaume, et al.
Publicado: (2019)

Lipid A analog CRX-527 conjugated to synthetic peptides enhances vaccination efficacy and tumor control
por: Tondini, Elena, et al.
Publicado: (2022)

OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum
por: van der Sluis, Tetje C., et al.
Publicado: (2023)

Enhanced Cross-Presentation and Improved CD8(+) T Cell Responses after Mannosylation of Synthetic Long Peptides in Mice
por: Rauen, Judith, et al.
Publicado: (2014)

Cytofast: A workflow for visual and quantitative analysis of flow and mass cytometry data to discover immune signatures and correlations
por: Beyrend, Guillaume, et al.
Publicado: (2018)

Approaches to Improve Chemically Defined Synthetic Peptide Vaccines
por: Hos, Brett J., et al.
Publicado: (2018)

Combination of chemotherapy and PD-1 blockade induces T cell responses to tumor non-mutated neoantigens
por: Grimaldi, Alessio, et al.
Publicado: (2020)

Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models
por: Sow, Heng Sheng, et al.
Publicado: (2019)

The role of neoantigen in immune checkpoint blockade therapy
por: Yi, Ming, et al.
Publicado: (2018)

Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer
por: Peng, Hui, et al.
Publicado: (2022)

Predicting the efficacy of cancer vaccines by evaluating T-cell responses
por: van Duikeren, Suzanne, et al.
Publicado: (2013)

Cationic Nanoparticle-Based Cancer Vaccines
por: Heuts, Jeroen, et al.
Publicado: (2021)

Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma
por: Burrack, Adam L., et al.
Publicado: (2019)

PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
por: Kleinovink, Jan Willem, et al.
Publicado: (2017)

SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
por: Zhao, Mingxia, et al.
Publicado: (2019)

PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer
por: Liu, Peng, et al.
Publicado: (2022)

Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion
por: D'Alise, Anna Morena, et al.
Publicado: (2021)

The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC
por: Kanemura, Hiroaki, et al.
Publicado: (2022)

PD-L1 immune suppression in cancer: Tumor cells or host cells?
por: Kleinovink, Jan Willem, et al.
Publicado: (2017)

PD-1 Immune Checkpoint Blockade and PSGL-1 Inhibition Synergize to Reinvigorate Exhausted T Cells
por: Viramontes, Karla M., et al.
Publicado: (2022)

Identification of a neo-epitope dominating endogenous CD8 T cell responses to MC-38 colorectal cancer
por: Hos, Brett J., et al.
Publicado: (2019)

PD-L1 Expression Affects Neoantigen Presentation
por: Okada, Masahiro, et al.
Publicado: (2020)

Simplified Monopalmitoyl Toll‐like Receptor 2 Ligand Mini‐UPam for Self‐Adjuvanting Neoantigen‐Based Synthetic Cancer Vaccines
por: van den Ende, Thomas C., et al.
Publicado: (2020)

Local immunomodulation for cancer therapy: Providing treatment where needed
por: Fransen, Marieke F, et al.
Publicado: (2013)

Sunitinib Exerts In Vitro Immunomodulatory Activity on Sarcomas via Dendritic Cells and Synergizes With PD-1 Blockade
por: Ocadlikova, Darina, et al.
Publicado: (2021)

BET inhibitor JQ1 enhances anti-tumor immunity and synergizes with PD-1 blockade in CRC
por: Wang, Huijin, et al.
Publicado: (2022)

Combinatorial therapeutic approaches of photodynamic therapy and immune checkpoint blockade for colon cancer treatment
por: Hao, Yang, et al.
Publicado: (2022)

MC38 colorectal tumor cell lines from two different sources display substantial differences in transcriptome, mutanome and neoantigen expression
por: Schrörs, Barbara, et al.
Publicado: (2023)

Nanoparticle-enhanced radiotherapy synergizes with PD-L1 blockade to limit post-surgical cancer recurrence and metastasis
por: Guan, Xin, et al.
Publicado: (2022)

Intravesical VAX014 Synergizes with PD-L1 Blockade to Enhance Local and Systemic Control of Bladder Cancer
por: Tsuji, Shingo, et al.
Publicado: (2022)

Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapy [Image: see text]
por: Borst, Jannie, et al.
Publicado: (2021)

A third vaccination with a single T cell epitope confers protection in a murine model of SARS-CoV-2 infection
por: Pardieck, Iris N., et al.
Publicado: (2022)

Personalized neoantigen vaccine combined with PD-1 blockade increases CD8(+) tissue-resident memory T-cell infiltration in preclinical hepatocellular carcinoma models
por: Chen, Hengkai, et al.
Publicado: (2022)

Multiple instance learning to predict immune checkpoint blockade efficacy using neoantigen candidates
por: Lang, Franziska, et al.
Publicado: (2023)

Combinatorial PD-1 Blockade and CD137 Activation Has Therapeutic Efficacy in Murine Cancer Models and Synergizes with Cisplatin
por: Wei, Huafeng, et al.
Publicado: (2013)

MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment
por: Fang, Douglas D., et al.
Publicado: (2019)

Synergy of therapeutic vaccination against HPV16 oncogenic proteins and standard chemotherapeutics
por: Melief, Cornelis J, et al.
Publicado: (2014)

Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma
por: Holm, Jeppe Sejerø, et al.
Publicado: (2022)

Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies
por: Minnar, Christine M, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g587mpchquv61n356ec558t1kh